Jack Hadfield: An Important Step Toward Finding Measurable Biology in Long COVID
Jack Hadfield, Co-founder and Research Lead at Amatica Health, shared a post on LinkedIn about a recent article by Asghar Abbasi et al, published in Infection:
”Pieces of SARS-CoV-2 proteins were found in tiny blood particles in people with long COVID, even many months after infection.
These particles are called extracellular vesicles, or EVs. EVs are small packages released by cells into the blood that can carry proteins and other biological material.
In this study, researchers looked at 14 adults with long COVID symptoms including fatigue, shortness of breath, exercise intolerance, and post-exertional malaise. On average, they were studied about 17 months after infection.
The team isolated EVs from blood samples and used mass spectrometry, a lab method that identifies molecules by their molecular pattern, to look for pieces of SARS-CoV-2 proteins.
They detected 65 viral protein fragments linked to a viral protein called Pp1ab in 22 of 56 samples. The authors also reported that each participant had at least one SARS-CoV-2 peptide detected in EVs at some point across the sampling period.
They then used a more targeted confirmation method and verified one specific viral peptide in 12 of the 14 participants across multiple time points. None of the 20 pre-pandemic control samples showed the same signal.
This does not prove live virus is still present. It does not prove these protein fragments are causing symptoms. And it does not establish a clinical test.
But it may point to an ongoing biological signal in at least some people with long COVID, and that is why this paper is worth paying attention to.
The main caveats are also important. This was a very small study. It was a short correspondence paper, not a large validation study. The signal was not found in every sample, and the study did not include a key comparison group of people who had COVID and recovered without long COVID.
So the balanced takeaway is this: early evidence, not proof, but a potentially important step toward finding measurable biology in long COVID.
The details above come directly from the paper’s cohort description, EV proteomics methods, peptide findings, targeted validation, and control comparisons”
Title: Possible long COVID biomarker: identification of SARS-CoV-2 related protein(s) in Serum Extracellular Vesicles
Authors: Asghar Abbasi, Ritin Sharma, Nathaniel Hansen, Patrick Pirrotte, William W. Stringer
Read the Full Article on Infection

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 18, 2026, 15:11Vansh Yaduvanshi: Why Compatible Blood Groups Do Not Always Mean Compatible Blood
-
Nov 18, 2026, 14:49Estetrol-Based Contraception in PCOS and Its Effects on Coagulation – RPTH Journal
-
Nov 18, 2026, 14:41Factor V Deficiency: Diagnostic Challenges and the Role of Combined Factor V and VIII Deficiency
-
Nov 18, 2026, 14:29Maxime Dely: When Patient Encounters Become Life Lessons
-
Nov 18, 2026, 14:23Basanta Khatiwada: Advancing Haematology Through Research and Innovation at HAEMATOCON 2026
-
Nov 18, 2026, 14:13Alvin Katumba: Sickle Cell Disease Research Recognised With a 2026 ASH Abstract Achievement Award
-
Nov 18, 2026, 13:34Vincenzo De Angelis: Strengthening Plasma Management and Quality Control in Eastern Europe
-
Nov 18, 2026, 13:34Standardizing Bleeding Outcome Assessment in Hemophilia Clinical Trials – JTH
-
Nov 18, 2026, 13:34Nicolas Gendron: The Ecological Transition in Thrombosis and Haemostasis